Pipeline
A Broad Pipeline Approaching the Clinic
Using a delivery-centric approach to unlock the power of genetic medicines across many disease areas.
| Program |
Discovery
Lead Optimization
IND Enabling
Clinical Development
|
|
|---|---|---|
|
Targeted LNPs
|
AERA-109: Targeted In Vivo CAR-T for Autoimmune Disease |
mid IND Enabling phase
|
|
AERA-109 is a targeted in vivo CAR-T therapy designed to treat multiple B cell-mediated autoimmune diseases. AERA-109 leverages Aera’s proprietary targeted lipid nanoparticle (tLNP) delivery platform and CAR-T technology to reprogram immune cells directly inside the body, offering a potentially transformative approach to treating serious autoimmune conditions with greater precision and improved safety. Aera’s preclinical data with this approach has demonstrated deep depletion of B cells in blood and tissue in humanized mouse models and non-human primates. Aera plans to advance AERA-109 into clinical development in mid-2026. |
||
|
Next Gen Targeted LNP Programs |
Discovery phase
|
|
|
Antibody-Oligo Conjugates
|
Cardiac Targeted AOC |
Lead Optimization Phase
|
|
Other Muscle Targeted AOC |
Discovery phase
|
|
|
Protein Nano-Particles
|
CNS Targeted PNP |
Discovery phase
|
Targeted LNPs
AERA-109: Targeted In Vivo CAR-T for Autoimmune Disease
AERA-109 is a targeted in vivo CAR-T therapy designed to treat multiple B cell-mediated autoimmune diseases. AERA-109 leverages Aera’s proprietary targeted lipid nanoparticle (tLNP) delivery platform and CAR-T technology to reprogram immune cells directly inside the body, offering a potentially transformative approach to treating serious autoimmune conditions with greater precision and improved safety. Aera’s preclinical data with this approach has demonstrated deep depletion of B cells in blood and tissue in humanized mouse models and non-human primates. Aera plans to advance AERA-109 into clinical development in mid-2026.
Next Gen Targeted LNP Programs
Antibody-Oligo Conjugates
Cardiac Targeted AOC
Other Muscle Targeted AOC
Protein Nano-Particles
CNS Targeted PNP